Tests ALTO-207 against placebo in adults with treatment-resistant depression
Tests whether ALTO-207 affects depression symptoms in adults with treatment-resistant depression.
Plain-language title generated from the registry record
Registry title: ALTO-207 in Adults With Treatment-resistant Depression (TRD)
Key facts
- Where
- Albany, Amherst, Ann Arbor, Annapolis, Austin, Baltimore, Bloomfield Hills, Bryan, Cary, Cedarhurst, Charlotte, Chino, Cincinnati, Dallas, Dayton, Dothan, East Providence, Fairfax, Fort Worth, Galveston, Garfield Heights, Grand Rapids, Houston, Indianapolis, Irving, La Jolla, Lewiston, Los Angeles, Marietta, Naperville, North Myrtle Beach, Oakland, Oceanside, Palo Alto, Phoenix, Pikesville, Plano, Rockville, Sacramento, Saint Augustine, San Diego, San Jose, Savannah, Seattle, Snellville, South Charleston, St Louis, Syracuse, Toms River, Valley Village, Wilton, and Worcester, United StatesSee the 53 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07553637, who can take part
Where in United States
- AlbanyAlbany, United StatesTaking people
- AmherstAmherst, United StatesTaking people
- Ann ArborAnn Arbor, United StatesTaking people
- AnnapolisAnnapolis, United StatesNo longer taking part
- AustinAustin, United StatesNot yet recruiting
- BaltimoreBaltimore, United StatesNot yet recruiting
- Bloomfield HillsBloomfield Hills, United StatesTaking people
- BryanBryan, United StatesNot yet recruiting
- CaryCary, United StatesTaking people
- CedarhurstCedarhurst, United StatesTaking people
- CharlotteCharlotte, United StatesTaking people
- ChinoChino, United StatesTaking people
- CincinnatiCincinnati, United StatesTaking people
- DallasDallas, United StatesTaking people
- DaytonDayton, United StatesNot yet recruiting
- DothanDothan, United StatesTaking people
- East ProvidenceEast Providence, United StatesTaking people
- FairfaxFairfax, United StatesTaking people
- Fort WorthFort Worth, United StatesTaking people
- GalvestonGalveston, United StatesNot yet recruiting
- Garfield HeightsGarfield Heights, United StatesTaking people
- Grand RapidsGrand Rapids, United StatesNot yet recruiting
- HoustonHouston, United StatesTaking people
- HoustonHouston, United StatesTaking people
- IndianapolisIndianapolis, United StatesTaking people
- IrvingIrving, United StatesTaking people
- La JollaLa Jolla, United StatesNot yet recruiting
- LewistonLewiston, United StatesTaking people
- Los AngelesLos Angeles, United StatesTaking people
- MariettaMarietta, United StatesTaking people
- NapervilleNaperville, United StatesTaking people
- North Myrtle BeachNorth Myrtle Beach, United StatesNot yet recruiting
- OaklandOakland, United StatesTaking people
- OceansideOceanside, United StatesTaking people
- Palo AltoPalo Alto, United StatesNot yet recruiting
- PhoenixPhoenix, United StatesTaking people
- PikesvillePikesville, United StatesTaking people
- PlanoPlano, United StatesTaking people
- RockvilleRockville, United StatesTaking people
- SacramentoSacramento, United StatesTaking people
- Saint AugustineSaint Augustine, United StatesTaking people
- San DiegoSan Diego, United StatesTaking people
- San JoseSan Jose, United StatesTaking people
- SavannahSavannah, United StatesTaking people
- SeattleSeattle, United StatesNo longer taking part
- SnellvilleSnellville, United StatesTaking people
- South CharlestonSouth Charleston, United StatesNot yet recruiting
- St LouisSt Louis, United StatesTaking people
- SyracuseSyracuse, United StatesTaking people
- Toms RiverToms River, United StatesTaking people
- Valley VillageValley Village, United StatesTaking people
- WiltonWilton, United StatesNot yet recruiting
- WorcesterWorcester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alto Neuroscience
- Trial code
- NCT07553637
- Record updated
- 26 October 2026
- Original description
The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.Read full original descriptionShow less
A Randomized, Double-blind, Placebo-controlled Trial of ALTO-207 in Adults With Treatment-resistant Depression
The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.
Inclusion: Male and female participants, ages 18 to 75 years, inclusive, at the time of signing the ICF; Prior diagnosis of MDD without psychotic symptoms (in the current episode) and have confirmatory diagnosis of current MDD (moderate to severe); Failure to respond (<50% improvement) to at least 2-5 antidepressant treatments (including the current treatment); Currently taking a stable dose of at least 1 but no more than 2 oral antidepressants at baseline.
Exclusion: Concurrent use of any prohibited medications or substance use disorder; Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device; Evidence of unstable medical condition; Diagnosed bipolar disorder or a psychotic disorder or symptoms; Significant current PTSD symptoms or history of PTSD; Has a history of hypersensitivity or allergic reaction to ALTO-207 or any of its components/excipients; Clinically significant current impulse control difficulties.